Hubly Surgical, a leader in neurosurgical innovation, has successfully closed its Series Seed funding round at an oversubscribed $3 million. The investment comes on the heels of the company's recent FDA Clearance for the Hubly Drill, a groundbreaking and patented device poised to revolutionize bedside neurosurgery.

The oversubscribed $3 million Seed round comprises several key investors: the vast majority of the raise came from the Hubly Surgical commission-only distributor sales force, existing Hubly investors, and from neurosurgeons and physician-centric funds.